Hormone Refractory Prostate Cancer (HRPCA) Market Size, Share, Industry, Forecast and outlook (2024-2031)
Published: 2024 January 24
SKU : PH3383
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Request new version
FAQ’s
What are the segments covered in Hormone Refractory Prostate Cancer (HRPCA) Market?
The segments are By Treatment type, By End-users, and By Region.
Who are the key players in Hormone Refractory Prostate Cancer (HRPCA) Market?
Key players are AbbVie Inc, Acceleron Pharma, Inc, AB Science SA, AstraZeneca Plc, Astellas Pharma Inc, Sanofi S.A, Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company and Johnson and Johnson.
Related Reports
pharmaceuticalsFoveal Atrophy Market Size, Share, Industry, Forecast and Outlook (2023-2030)
Published: 2023 September 26
Starting from
$4350
pharmaceuticalsChronic Disease Management Market Size, Share, Industry, Forecast and Outlook (2023-2030)
Published: 2023 September 26
Starting from
$4350
pharmaceuticalsAlpha-1 Antitrypsin Deficiency Therapy Market Size, Share, Industry, Forecast and Outlook (2023-2030)
Published: 2023 November 29
Starting from
$4350
pharmaceuticalsVisceral Leishmaniasis Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)
Published: 2023 November 29
Starting from
$4350
pharmaceuticalsFriedreich's Ataxia Market Size, Share, Industry, Forecast and Outlook (2023-2030)
Published: 2023 November 29
Starting from
$4350
pharmaceuticalsPars Planitis Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)
Published: 2023 November 29
Starting from
$4350